• Yu Kawazoe, Tetsuya Sato, Noriko Miyagawa, Yuta Yokokawa, Shigeki Kushimoto, Kyohei Miyamoto, Yoshinori Ohta, Takeshi Morimoto, and Hitoshi Yamamura.
• Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
• Blood Purif. 2018 Jan 1; 46 (4): 309-314.

Background/AimsThe optimal duration of hemoperfusion therapy with a polymyxin B-immobilized fiber column has not yet been verified.MethodsThis analysis examined whether hemoperfusion therapy with a polymyxin B-immobilized fiber column lasting longer than 2 h (prolonged polymyxin) improved outcomes for patients with septic shock compared to 2-h polymyxin therapy (sub-analysis of data from the DESIRE trial).ResultsThe 2-h and prolonged polymyxin groups contained 22 and 14 patients, respectively. Both groups had similar characteristics. The polymyxin duration per session in the prolonged polymyxin group was significantly longer (median, 5.5 h) than in the 2-h polymyxin group (p < 0.01). The 28-day mortality rate was significantly higher in the 2-h polymyxin group (7, 31.8%) than in the prolonged polymyxin group (0, 0%; p = 0.019).ConclusionProlonged polymyxin therapy might be associated with better clinical outcomes than 2-h polymyxin therapy in patients with septic shock. Video Journal Club "Cappuccino with Claudio Ronco" at http://www.karger.com/?doi=491744.© 2018 S. Karger AG, Basel.

19 keywords...

hide…